

# 2018 Lifetime Achievement Award



Henry Kitchener, MD

For his leadership in randomized non-pharma clinical trials, Chairmanship of the Gynecologic Cancer Intergroup (GCIIG), founding the 'State-of-the-Art' workshops in Manchester and developing the Cervical Cancer Research Network (CCRN).

## About Dr. Henry Kitchener

Henry Kitchener graduated in Medicine at Glasgow University, qualifying in 1975, and went on to train in Obstetrics and Gynaecology. He completed his higher degree in the MRC Virology Unit where he studied the viral aetiology of cervical cancer. Following a Clinical lectureship in the University of Singapore, he returned to Glasgow to undertake subspecialty training in Gynaecological Oncology which he completed in 1988. He then moved to Aberdeen as Consultant and Senior Lecturer. In 1996 he was appointed to a newly established Chair in Gynaecological Oncology in the University of Manchester, remaining in that post until retiring in 2016, when he received the title of Professor Emeritus.

In Manchester, he developed and led a comprehensive multidisciplinary clinical service in Gynaecological Oncology which in collaboration with Gordon Jayson has evolved into a leading academic centre. A key element has been the establishment of academic training in Gynaecological Oncology through a programme of clinical research fellowships followed by subspecialist training within clinical


lectureships. This model has established Manchester as a destination of choice for high flyers wishing to become academic Gynaecological Oncologists, essential for the long-term health of our speciality.

Professor Kitchener's research has been principally in the field of clinical trials in gynaecological surgery and cervical cancer prevention. In the early 1990's he led an early pioneering trial of hysteroscopic surgery, which resulted in a significant reduction in hysterectomy rates. A major area of his work has been in cervical screening, most notably the use of primary HPV testing in the ARTISTIC trial, but also trials of automated cytology, HPV triage for low grade cytology, and HPV as test of cure. These have informed the development of screening protocols in the UK and internationally. He has also been involved in international trials of prophylactic vaccination, and led trials of novel treatment for VIN, including pioneering studies of therapeutic vaccination, photodynamic therapy and the use of preadjuvant imiquimod. In endometrial cancer, the landmark ASTEC trial demonstrated that lymphadenectomy did not improve overall survival, and the ongoing STATEC trial has been designed to demonstrate whether lymph node status can effectively select women for adjuvant therapy.

Amongst a number of leadership roles, he was responsible for a 1996 report to the Royal College of Obstetrics and Gynaecology recommending the establishment of Gynaecological Cancer Centres across the UK in order to ensure specialised care for all women within the NHS. This had been fully implemented within 10 years. He has been Chair of the Advisory Committee for Cervical Screening in England since 2005, including a national pilot of HPV primary screening since 2013. He is a former President of the British Society of Colposcopy and Cervical Pathology. He has chaired CRUK's CTAAC, which is the main awarding body for Cancer trials in the UK. In the University of Manchester he has held the post of Director of the Institute of Cancer Sciences. He is a former Chair of the Gynaecological Cancer InterGroup and the initial chair of the Cervical Cancer Research Network.

Professor Kitchener was elected to the UK Academy of Medical Sciences in 2007.

## 2018 Excellence in Teaching Award



**Peter Heintz, MD, PhD and the the Dutch School of Gynaecologic Oncology and Pelvic Surgery**

**For the successful development (10+ years) of the Dutch School Fellowship and Gynaecological Cancer Nurses Programme in Indonesia.**

### About Prof. Peter Heintz

The career of Prof. Heintz is characterized by a strong interest in women with cancer, in the western world as well as in the developing world. Prof. Heintz received his OB/GYN and oncology training at the Leiden University Medical Centre and the Netherlands Cancer Institute. At the beginning of his career, gynaecologic oncology as a recognized subspecialty only existed in North America and Australia. Thus, he travelled to the University of California Los Angeles in the USA to finalize his training in gynaecological cancer from summer 1983 to summer 1984, under the supervision of prof. Leo Lagasse. He then returned to Leiden University to obtain his PhD.

In the early 1980's he was a Founding Member and President of the Dutch Society of Gynecologic Oncology to promote the development and recognition of gynaecologic oncology in the Netherlands. This proved to be the beginning of the recognition of gynaecologic oncology in the Netherlands.

Internationally, he was one of the four founding members of the International Gynecologic Cancer Society (IGCS) which included Neville Hacker, Paul Morrow, and Denny DePetrillo. Throughout the years, he served as a member of the IGCS Scientific Committee for ten Biennial Meetings and held positions of Board Member, Vice President and President. He also served as an editor of the International Journal of Gynaecological Cancer from 1987-2002 and served as a Council Member of the European Society of Gynecologic Oncology (ESGO) from 1999-2002. Prof. Heintz was one of the forces behind revitalization of the European Society of Gynecologic Oncology (ESGO). Together with his European colleagues he succeeded in turning this society into a vivid partner of IGCS in the global fight against cancer.

In the past ten years, Prof. Heintz has received the IGCS Excellence Award (2008), the Doctor Honoris Causa in Medicine, (Universitas Indonesia, Jakarta, 2011) and the Royal Honour of the Dutch Queen: Officer in the Order of Oranje Nassau (2012).

From 1988-2006, he was Professor of Obstetrics and Gynaecology, including Gynaecologic Oncology at the University Medical Centre Utrecht. Twenty-seven PhD students have successfully completed their PhD research under his supervision. He is also the author/co-author of more than 230 publications of which 173 are presently listed in PubMed.

#### About the Dutch School of Gynaecologic Oncology and Pelvic Surgery

Prof. Heintz's interest in cancer care in developing countries started in 1986 when a young Indonesian gynaecologist, Dr. Andrijono, inquired about gynaecologic oncology training at the Netherlands Cancer Institute. This was the beginning of a long-standing relationship and friendship with Professor Andrijono and his staff at the University of Indonesia in Jakarta. When Professor Heintz moved to Utrecht University, he continued to train gynaecologists from Jakarta and visited Indonesia to teach on a yearly basis. In 2002, the Indonesian Society of Gynaecologic Oncology was founded and from that time on, Indonesia had its own fellowship programme. In this programme, Professor Heintz worked together with Indonesian colleagues to facilitate the founding of the Dutch School of Gynaecologic Oncology and Pelvic Surgery in 2007. At the Dutch School, gynaecologists and gynaecologic oncologists of several Dutch teaching hospitals worked together with Indonesian

teaching hospitals to train young Indonesian gynaecologists in oncology and pelvic surgery.

The cooperation between the Indonesian Medical Schools/Universities and the Dutch School includes the following activities:

- The Dutch School sends visiting teachers for 2 weeks twice each year to the medical schools with a gynaecologic oncology fellowship programme (Jakarta, Bandung, Surabaya).
- Visiting teachers/professors travel twice a year to a few other medical schools on request.
- Gynaecologic Oncology Fellowships of 3-6 months are conducted in Dutch Cancer Centers for young gynaecologists (<40 years of age) who had finished the Indonesian Fellowship Programme.
- Short Fellowships of 4 months are conducted in a dedicated area of surgical gynaecology: (i.e. laparoscopy, hysteroscopy, etc...).

Between 1988 and 2018, 44 Indonesian gynaecologists and one pathologist received additional training in the Netherlands. From 2007 to present, professor Heintz has served as the Chairman of the Dutch School of Gynaecologic Oncology and Pelvic Surgery. All Dutch teachers are gynaecologic oncologists from Dutch Academic Cancer Centres, and they work free of charge. Only costs of travelling are reimbursed.

In 2011, the Dutch School started a visiting teacher programme for oncology nurses and the head of this programme has been Professor Saskia Teunissen. Based on these experiences, it was clear that a sub-specialization programme for nurses was needed. In 2014, the first class of 30 nurses started with the training at the Dharmais Cancer Hospital in Jakarta. In 2015, the second class of 30 nurses started in Yogyakarta. The teachers are senior oncology nurses from the University Medical Center Utrecht and the Academic Hospice Demeter, De Bilt. At this moment, 60 nurses have been examined and received their oncology sub-specialization certificate. This year, the programme will be continued with an additional two courses on palliative care and pain management, and in 2019, two new classes of nurses will start their oncology sub-specialization.

The activities of the Dutch School are supported by gifts of several Dutch charity foundations. The Indonesian partners of the Dutch School take care of the local hospitality in their country. The fellowship programme

was partly sponsored by IGCS. Detailed information is available on: [www.dutchschool.nl](http://www.dutchschool.nl).

## 2018 Global Humanitarian Award



**Edward L Trimble, MD, MPH and  
the NCI Center for Global Health**

**For developing initiatives and collaborating with low- and middle-income countries to support cancer control planning, build capacity and support cancer research and training. They have been instrumental in assisting IGCS to make inroads into under penetrated regions of the world.**

### About Dr. Edward Trimble

**In 2011 Dr. Harold Varmus, then Director of the US National Cancer Institute (NCI) appointed Dr. Trimble the founding Director of NCI's new Center for Global Health (CGH). Under Dr. Trimble's leadership CGH has become the coordinating point for NCI's work to strengthen global cancer research, to train future generations of global cancer researchers, and to help translate research into policy for cancer control. NCI CGH has been recognized worldwide for its work in the development of affordable cancer technology, national cancer control planning, and training.**

**From 1991 to 2011 Dr. Trimble worked in NCI's Division of Cancer Treatment and Diagnosis, with responsibility for national and**

international NCI-sponsored treatment trials in gynecologic cancer, as well as cancer trials for the elderly, adolescents and young adults, international collaboration in cancer clinical trials, and strengthening assessment of patient-reported outcomes and health-related quality of life in cancer trials. He spearheaded the NCI's Clinical Announcements regarding chemoradiation for cervical cancer (1999) and intraperitoneal chemotherapy for ovarian cancer (2006), both of which changed the standard of care for women with gynecologic cancer. For his work at the US NCI Dr. Trimble has received two Public Health Service Commendation Medals, six NIH Merit Awards, and the NCI Director's Gold Star Award.

Dr. Trimble graduated from Harvard University (BA), the Johns Hopkins University School of Medicine (MD), and the Johns Hopkins University Bloomberg School of Public Health (MPH). He trained in obstetrics/gynecology at Vanderbilt University Medical Center and in gynecologic oncology at Memorial Sloan-Kettering Cancer Center. He is board-certified in obstetrics and gynecology, as well as in gynecologic oncology, by the American Board of Obstetrics and Gynecology.

#### About the NCI Center for Global Health (CGH)

The National Cancer Institute (NCI) established the Center for Global Health (CGH) in 2011 to help reduce the global burden of cancer. CGH develops initiatives and collaborates with other NCI divisions, NCI-designated cancer centers, and countries to support cancer control planning, build capacity, and support cancer research and cancer research networks in low- and middle-income countries (LMICs).

## 2018 Award for Community Advancement in Low- & Middle-Income Countries



**Agnes Binagwaho, MD, PhD**

**For the initiation and supervision of several successful community vaccination programmes including the very successful HPV vaccination programme in Rwanda and the establishment of a family planning campaign.**

### **About Prof. Agnes Binagwaho**

**In 2017, Professor Binagwaho was named Vice Chancellor of the University of Global Health Equity, an initiative of Partner In Health. From 2002-2016, she served the Rwandan Health Sector in high-level government positions, first as the Executive Secretary of Rwanda's National AIDS Control Commission, then as Permanent Secretary of the Ministry of Health in 2008. In 2011, she was appointed as the Minister of Health, serving five years in this position.**

**During Dr. Binagwaho's tenure, the Rwandan Ministry of Health is responding to the growing burden of non-communicable diseases through a variety of interventions that include expanding screenings, follow-up services, and palliative care. To ensure the health system meets the needs of all Rwandans, even the most vulnerable, Dr.**

**Binagwaho and her team applied data from the Global Burden of Disease (GBD) study to drive many national health policies.**

**After studying the data and charting out the health landscape, Dr. Binagwaho and her team identified that cancer, especially for women, was a major disease that they could tackle. The Ministry of Health determined that they could mitigate the impact of cancer in two ways: consultation and vaccination. After finding out about a vaccine to prevent cervical cancer and with the support of Rwanda's First Lady, Dr. Binagwaho led Rwanda's effort to roll out a national vaccination campaign. Over 90% of girls in school were immunized against human papillomavirus (HPV) as a result, making Rwanda the first African nation to introduce this vaccine.**

**As Minister of Health, Dr. Binagwaho also oversaw the development and implementation the Adolescent Sexual Reproductive Health and Rights Policy. This Policy and its Strategic Plan serves to guide interventions concerning Adolescent Sexual and Reproductive Health and Rights, particularly to respond to challenges related to HIV/AIDS and unwanted pregnancies.**

**She is a Senior Lecturer in the Department of Global Health and Social Medicine at Harvard Medical School, a Professor of the Practice of Global Health Delivery at the University of Global Health Equity in Rwanda, and an Adjunct Clinical Professor of Pediatrics at the Geisel School of Medicine at Dartmouth.**

**She has held an array of leadership and advisory positions on national and international scale. Since 2016, she has been a member of the American National Academy of Medicine and since 2017, a fellow of the African Academy of Sciences. Presently, she serves on: the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries; the Task Force on Global Advantage; several editorial boards of the scientific journals; the Advisory Committee Member of the Disease Control Priorities 3 (DCP3); and multiple Lancet Commissions, including the Lancet Commission on Women and Health; the Lancet Commission on Investing in Health; the Lancet-O'Neill Institute Georgetown University Commission on Global Health and Law, the Harvard Global Equity Initiative – Lancet Commission on Global Access to Pain Control and Palliative Care, the Lancet Commission for the Future of Health in Sub-Saharan Africa, the Lancet Diabetes & Endocrinology Commission, and**

**the Lancet NCDI Poverty Commission: Reframing NCDs and Injuries of the Poorest Billion.**

**In 2015, she received the annual Roux Prize and Ronald McDonald House Charities Award of Excellence. With over 150 peer-reviewed publications, her academic engagements include research across areas including health equity, HIV/AIDS, information and communication technologies (ICT) in e-health, and pediatric care delivery systems.**